XBIO Xenetic Biosciences, Inc.

Nasdaq xeneticbio.com


$ 4.39 $ 0.00 (0 %)    

Friday, 17-Oct-2025 05:47:43 EDT
QQQ $ 591.96 $ 0.00 (0 %)
DIA $ 455.81 $ 0.00 (0 %)
SPY $ 653.35 $ 0.00 (0 %)
TLT $ 91.53 $ 0.00 (0 %)
GLD $ 399.29 $ 0.00 (0 %)
$ 4.39
$ 4.81
$ 4.35 x 99
$ 4.38 x 10
-- - --
$ 2.20 - $ 13.93
136,530
na
6.77M
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-22-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-29-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-10-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 03-30-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 micron-galecto-and-xenetic-lead-this-weeks-benzinga-stock-ranking-surges

Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companies that stood out this week.

 xenetic-biosciences-prices-offering-of-735k-common-shares-at-612shr-for-gross-proceeds-of-45m

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on ad...

 4-stocks-in-the-same-sector-just-made-a-huge-leap-in-momentum-rankings

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam a...

 xenetic-biosciences-q2-eps-045-beats-065-estimate-sales-589897k-miss-720000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $...

 xenetic-biosciences-announces-first-patient-dosing-in-exploratory-clinical-study-of-systemic-dnase-i-in-combination-with-folfirinox-for-advanced-or-metastatic-pancreatic-cancer

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, P...

 xenetic-biosciences-q1-eps-059-beats-072-estimate-sales-59326k-miss-67000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $...

 hc-wainwright--co-reiterates-neutral-on-xenetic-biosciencesto-neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

 hc-wainwright--co-reiterates-neutral-on-xenetic-biosciencesto-neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

 xenetic-biosciences-q4-eps-068-misses-020-estimate-sales-64882k-beat-23000k-estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of...

 xenetic-biosciences-net-loss-for-the-year-ended-december-31-2024-was-4m-ended-the-year-with-62m-of-cash

Summary of Financial Results for Fiscal Year 2024Net loss for the year ended December 31, 2024 was approximately $4.0 million. ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION